导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.77% | 1064/4773 |
| 近一周 | -1.13% | 1722/5465 |
| 近一月 | -6.77% | 4318/5421 |
| 近一季 | -14.14% | 4244/5231 |
| 近半年 | 5.11% | 817/4920 |
| 近一年 | 8.74% | 1287/4394 |
| 近两年 | 78.60% | 867/2954 |
| 近三年 | 47.64% | 609/2253 |
| 成立以来 | 81.68% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.95% 3464/4961 |
41.69% 740/5312 |
- - |
- - |
| 2025 | 31.43% 1237/4813 |
-2.02% 2831/3635 |
0.12% 2759/4076 |
39.50% 803/4524 |
-3.95% 3365/4813 |
| 2024 | 13.31% 1153/3463 |
-1.94% 1299/2808 |
-2.99% 1285/3014 |
18.59% 982/3129 |
0.45% 1211/3463 |
| 2023 | -14.41% 1601/2656 |
5.26% 806/2280 |
-5.47% 1469/2385 |
-7.63% 1598/2515 |
-6.89% 1960/2655 |
| 2022 | -25.00% 1280/2207 |
-18.40% 1330/1919 |
6.84% 593/2016 |
-17.66% 1630/2113 |
4.46% 543/2208 |
| 2021 | 7.81% 489/1822 |
-6.18% 984/1255 |
16.42% 203/1330 |
-2.81% 594/1466 |
1.57% 871/1822 |
| 2020 | 51.00% 162/1250 |
-1.73% 232/1028 |
21.20% 242/1067 |
9.85% 609/1164 |
15.42% 208/1184 |
| 2019 | 33.56% 430/1092 |
25.49% 462/754 |
-7.35% 553/804 |
5.26% 157/850 |
9.14% 253/918 |
| 2018 | -30.81% 479/834 |
- - |
- - |
- - |
-13.73% 550/691 |
| 2017 | 13.60% 260/714 |
- - |
- - |
- - |
- - |
| 2016 | -16.57% 382/605 |
- - |
- - |
- - |
- - |
| 2015 | 29.61% 78/575 |
- - |
- - |
- - |
- - |
| 2014 | 27.50% 174/237 |
- - |
- - |
- - |
- - |
| 2013 | 22.32% 13/186 |
- - |
- - |
- - |
- - |
| 2012 | -2.82% 133/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 东吴中证新兴指数 VS. 长安沪深300非周期A(740101) |